- Argonaut Manufacturing Services has appointed biotechnology veteran Rick Hancock as Chief Executive Officer.
- The company recently expanded its Carlsbad, California campus, opening a new drug product facility that increases its commercial-scale capacity fivefold.
Argonaut Manufacturing Services, a contract development and manufacturing organisation (CDMO) specialising in aseptic drug product manufacturing and the production of life science and diagnostic products, has appointed Rick Hancock as Chief Executive Officer (CEO).
Rick brings over 40 years of leadership experience in CDMOs and pharmaceutical development companies. He has served on Argonaut’s Board of Directors for nine years, playing a key role in the company’s transition from life sciences and diagnostics into drug product manufacturing.
“Rick’s expertise and track record make him a great leader for Argonaut. He brings a rare combination of industry insight and operational excellence that reinforces our commitment to deliver premium services to our clients.”
Board member Paul Grossman
As CEO, Rick will lead Argonaut’s continued growth, including the expansion of its Carlsbad, California campus. The company recently held the grand opening of a new drug product facility, featuring an Annex 1 compliant isolator-based filling line capable of filling vials, prefilled syringes, and cartridges. This investment increases Argonaut’s commercial-scale capacity fivefold, enhancing its ability to serve clients globally.
Rick commented, “Argonaut’s future is bright, and our mission remains to help clients overcome complex challenges and deliver life-changing products to patients faster.”
